<DOC>
	<DOCNO>NCT00002940</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness hydroxyurea treat patient Epstein-Barr virus-associated primary CNS lymphoma AIDS .</brief_summary>
	<brief_title>Hydroxyurea Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma AIDS</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate objective response rate PCNSL AIDS patient treat hydroxyurea . II . Investigate whether level Epstein-Barr virus ( EBV ) DNA blood cerebral spinal fluid correlate PCNSL disease activity . OUTLINE : This open label pilot study . Patients receive oral hydroxyurea tid . A course hydroxyurea consist 4 week therapy . On day 28 , first course treatment , tumor size analyze MRI . If reduction tumor size see day 28 , hydroxyurea dose increase . If CR PR demonstrate , patient continue treatment original dose . MRI evaluation take day 56 treatment . Patients progressive disease evaluation consider treatment response . PROJECTED ACCRUAL : 15-25 patient enrol . Approximately 8-10 patient accrue annually .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven EBVassociated primary CNS lymphoma HIV infection confirm positive ELISA Western blot PATIENT CHARACTERISTICS : Age : Open child adult age Performance Status : Karnofsky least 50 % Life Expectancy : At least 4 week Hematopoietic : Hemoglobin least 6.9 gm/dL ANC least 500/mm3 Platelet count least 50,000/mm3 Hepatic : Bilirubin great 1.5 x upper limit normal ( ULN ) ( 1.5 2.5 x ULN receive indinavir ) Renal : Creatinine great 1.5 x ULN Cardiovascular : Not specify Other : Not pregnant nursing Contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : Prior concurrent antiretroviral therapy allow No prior EBVassociated primary CNS lymphoma therapy within 1 week study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
</DOC>